Kratom Potency Compared to Oxycodone 5mg
Kratom's active alkaloids, particularly 7-hydroxymitragynine and its human metabolite mitragynine pseudoindoxyl, are significantly MORE potent than oxycodone 5mg on a per-milligram basis at opioid receptors, though the clinical effect depends heavily on product variability and alkaloid content.
Understanding the Pharmacologic Comparison
The comparison is complex because kratom is not a single compound but contains multiple alkaloids with varying opioid receptor activity:
Oxycodone Reference Point
Using CDC morphine milligram equivalent (MME) conversion tables, oxycodone 5mg equals 7.5 MME (conversion factor 1.5) 1, 2. This provides a standardized reference for opioid potency comparison.
Kratom's Active Compounds
Primary alkaloids and their potency:
7-hydroxymitragynine (7-HMG): Animal studies demonstrate this alkaloid is more potent than morphine 3, 4. This compound acts as a potent and selective opioid agonist at mu- and delta-opioid receptors 4.
Mitragynine pseudoindoxyl: This is the critical finding for human pharmacology. When 7-HMG enters human plasma, it converts to mitragynine pseudoindoxyl, which is even more potent than 7-HMG itself 5. This metabolite forms to a much greater extent in humans than in preclinical species (mouse, rat, dog, monkey), meaning kratom's opioid effects in humans substantially exceed what animal studies predict 5.
Mitragynine: The most abundant alkaloid, acting as a partial mu-opioid receptor agonist with effects similar to morphine but lower intrinsic activity 4.
Critical Clinical Considerations
Product Variability Makes Direct Comparison Unreliable
The major problem: Commercial kratom products have extreme heterogeneity in alkaloid composition and concentration 6. Unlike pharmaceutical oxycodone with precise 5mg dosing 7, kratom preparations vary wildly in:
- Total alkaloid content
- Ratio of mitragynine to 7-HMG
- Presence of other active alkaloids (speciogynine, paynantheine, etc.) 8
Toxicity Profile Indicates High Potency
Kratom produces opioid-like toxidromes including respiratory depression that responds variably to naloxone 6. Cases demonstrate delayed or recurrent respiratory depression following initial naloxone reversal, suggesting sustained opioid receptor activation 6. This clinical pattern indicates substantial opioid potency.
The FDA has documented severe adverse effects including hallucinations, seizures, coma, and death associated with kratom use 3, supporting significant opioid receptor activity.
Semi-Synthetic Derivatives Exceed Natural Product
MGM-15, a semi-synthetic derivative of 7-HMG, shows greater mu- and delta-opioid receptor binding affinity than 7-HMG 9. Commercial tablets contain approximately 11mg MGM-15 9, marketed as "legal morphine" despite no human safety studies or FDA approval 9.
Clinical Management Implications
For patients using kratom:
- Assume opioid-level dependence potential exists 10
- Kratom use disorder meets DSM-5 criteria for opioid use disorder 10
- Methadone (mean maximum dose 98.6mg, range 35-190mg) effectively treats kratom use disorder 10
- Buprenorphine has also been used successfully 10
Critical pitfall: The species-specific metabolism in humans (conversion to mitragynine pseudoindoxyl) means kratom's opioid effects in humans are substantially greater than animal studies suggest 5. This creates a dangerous knowledge gap where users and clinicians may underestimate potency based on preclinical data.
Bottom Line
While receptor-level data suggests kratom alkaloids can exceed morphine potency, the lack of standardized dosing makes it impossible to state definitively whether a typical kratom dose is "more or less potent" than oxycodone 5mg. However, the pharmacologic evidence clearly demonstrates that kratom's active compounds—particularly in human metabolism—possess substantial opioid receptor potency that can equal or exceed traditional prescription opioids, with the added danger of unpredictable product composition and delayed toxicity 5, 6.